GE
77
12
TXT
70
4
LOW
58
2
KLAC
56
3
MDLZ
85
6
JWN
65
6
HON
63
3
MUR
52
2
PVH
64
4
ISRG
70
3
PRU
53
2
PX
18
3
ADT
25
2
VRSK
40
-2
MCHP
54
4
ZTS
25
5
CA
24
12
FITB
63
4
APH
62
6
HST
55
5
GE
77
12
TXT
70
4
LOW
58
2
KLAC
56
3
MDLZ
85
6
JWN
65
6
HON
63
3
MUR
52
2
PVH
64
4
ISRG
70
3
PRU
53
2
PX
18
3
ADT
25
2
VRSK
40
-2
MCHP
54
4
ZTS
25
5
CA
24
12
FITB
63
4
APH
62
6
HST
55
5
Financhill
Back

Cyclo Therapeutics 10K Form

Sell
22

CYTH
Cyclo Therapeutics

Last Price:
1.28
Seasonality Move:
3.1%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CYTH News And Ratings

See the #1 stock for the next 7 days that we like better than CYTH

CYTH Financial Statistics

Sales & Book Value

Annual Sales: $1.08M
Cash Flow: $-4.29M
Price / Cash Flow: 0
Annual Sales: $0.17
Price / Book: 7.3

Profitability

EPS (TTM): -1.31000
Net Income (TTM): $-20.06M
Gross Margin: $992.04K
Return on Equity: -3987.27%
Return on Assets: -315.37%

Cyclo Therapeutics Earnings Forecast

Key Cyclo Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 24 years for CYTH is 92.16%.
  • The Selling, General & Administrative Expenses for CYTH have been equal to 526.37% of Gross Profit Margin.
  • The Research & Development expenses have been 1,317.51% of Revenue.
  • The Interest Expense is -0.68% of Operating Income.
  • The Net Earning history of CYTH is -1,863.35% of Total Revenues.
  • Per Share Earnings over the last 24 years have been positive in 13 years.

Cyclo Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CYTH
Website: cyclotherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.45
Quick Ratio: 1.11

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CYTH Technical Analysis vs Fundamental Analysis

Sell
22
Cyclo Therapeutics (CYTH) is a Sell

Is Cyclo Therapeutics a Buy or a Sell?